Sartorius and EMBL join forces to offer advanced training and science education
Sartorius is offering its expertise to enhance scientific education and practice.
Sartorius has announced a partnership with the European Molecular Biology Laboratory (EMBL) - one of the Europe’s leading research institutions with global reach. It includes many research sites, such as Heidelberg and Hamburg in Germany, Hinxton in the UK, Grenoble in France and Monterotondo in Italy.
Sartorius has joined the Corporate Partnership Program, EMBL’s platform for fostering advanced training collaboration and activities designed to connect industry to academia. The Corporate Partnership Program includes initiatives such as creating training courses, sponsoring conferences, organizing workshops for professionals and young scientists at the EMBL International Center for Advanced Training, EICAT, which offers numerous courses and conferences each year. In addition, Sartorius will also provide long-term support to EMBL’s school education program by funding travel bursaries each year for teachers to attend courses run by EMBL’s Learning Laboratory for the Life Sciences, ELLS.
Backing this well-known research institution, Sartorius is offering its expertise to enhance scientific education and practice. “By focusing on professional training at all levels, and ensuring that the next generation of young talent has access to the latest knowledge, we aim to support the scientific community to reach its maximum potential,” stated Karen Storm, Vice President of Marketing of the Lab Products & Services Division at Sartorius.
In parallel, EMBL is actively expanding its footprint by strengthening activities beyond the academic sphere into industry. “On behalf of EMBL, we welcome Sartorius to our family of Corporate Partners – working together will enhance our program of internationally renowned events, and we look forward to integrate their technologies and expertise into our offering,” added Prof. Matthias Hentze, Director, EMBL.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance